Overview

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study was done to find out which treatment, tacrolimus or sirolimus, leads to better long-term kidney function in kidney transplant patients.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Genzyme, a Sanofi Company
Roche Pharma AG
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Antilymphocyte Serum
Calcineurin Inhibitors
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Sirolimus
Tacrolimus
Thymoglobulin